van der Louw Elles, van den Hurk Dorine, Neal Elizabeth, Leiendecker Bärbel, Fitzsimmon Georgiana, Dority Laura, Thompson Lindsey, Marchió Maddelena, Dudzińska Magdalena, Dressler Anastasia, Klepper Joerg, Auvin Stéphane, Cross J Helen
Erasmus Medical Center Sophia Children's Hospital, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.
Wilhelmina Children's Hospital, University Medical Center Utrecht, The Netherlands.
Eur J Paediatr Neurol. 2016 Nov;20(6):798-809. doi: 10.1016/j.ejpn.2016.07.009. Epub 2016 Jul 17.
The ketogenic diet (KD) is an established, effective non-pharmacologic treatment for drug resistant childhood epilepsy. For a long time, the KD was not recommended for use in infancy (under the age of 2 years) because this is such a crucial period in development and the perceived high risk of nutritional inadequacies. Indeed, infants are a vulnerable population with specific nutritional requirements. But current research shows that the KD is highly effective and well tolerated in infants with epilepsy. Seizure freedom is often achieved and maintained in this specific patient group. There is a need for standardised protocols and management recommendations for clinical use.
In April 2015, a project group of 5 experts was established in order to create a consensus statement regarding the clinical management of the KD in infants. The manuscript was reviewed and amended by a larger group of 10 international experts in the KD field. Consensus was reached with regard to guidance on how the diet should be administered and in whom.
The resulting recommendations include patient selection, pre-KD counseling and evaluation, specific nutritional requirements, preferred initiation, monitoring of adverse effects at initiation and follow-up, evaluation and KD discontinuation.
This paper highlights recommendations based on best evidence, combined with expert opinions and gives directions for future research.
生酮饮食(KD)是一种已确立的、有效的治疗儿童耐药性癫痫的非药物疗法。长期以来,KD不被推荐用于婴儿期(2岁以下),因为这是一个发育的关键时期,且人们认为存在营养不足的高风险。的确,婴儿是具有特殊营养需求的脆弱群体。但目前的研究表明,KD对癫痫婴儿非常有效且耐受性良好。在这个特定患者群体中,癫痫发作常常能够得到控制并维持。临床使用需要标准化的方案和管理建议。
2015年4月,成立了一个由5名专家组成的项目组,以就婴儿KD的临床管理制定一份共识声明。该手稿由KD领域的10名国际专家组成的更大团队进行了审阅和修订。就饮食的给药方式及适用人群的指导意见达成了共识。
最终的建议包括患者选择、KD前咨询与评估、特定营养需求、首选的起始方式、起始及随访时不良反应的监测、评估及KD停用。
本文突出了基于最佳证据并结合专家意见的建议,并为未来研究指明了方向。